Abstract
The purpose of this rapid review is to investigate the development of the hepatic manifestations and challenges with SARS-COV-2 and multiple viral hepatitis infections. The literature on the most critical viral, genetic and immunological factors between SARS-CoV-2 and viral hepatitis was reviewed, and the most important interactions that occur with the host were identified in addition to the use of antivirals, another drug, and also the potential of defective viral genomes in antiviral inhibitors. This review specified that some types of viral hepatitis in SARS-COV-2 patients may be reduced reactivation and receive immunosuppressive therapy. We concluded from the current review that it is necessary to consider the special care of persons exposed to infection with SARS-CoV-2 to persons infected with viral hepatitis. In particular, advanced cases of the disease and their stages of treatment as it leads to liver dysfunction and life-threatening patient.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
